Clinical Genetics and Screening for Idiopathic Pulmonary Fibrosis (GENESI)
Background:
Idiopathic pulmonary fibrosis (IPF) is the most common and severe form of interstitial lung disease. Between 2% and 20% of patients with IPF have a family history of the disease, which is considered the strongest risk factor. Therefore, genetic testing has been increasingly considered as a potential tool to identify patients at risk of developing IPF.
According to some studies, genetic testing (particularly of MUC5B and TERT mutations) could be useful to rapidly identify unidentified and/or asymptomatic individuals (in families as well as in the general population) who have interstitial lung anomalies (ILA) that may indicate a initial stage of pulmonary fibrosis. Finding efficient screening methods and associated targeted treatments for IPF may be essential to improving the prognosis and quality of life of those suffering from this disease.
Objectives of the study:
The study involves two populations of study subjects:
- patients with FPF and sporadic IPF
- first-degree relatives of patients with FPF and sporadic IPF (biological relatives, not spouses)
The primary objective is to determine the prevalence rates of interstitial lung abnormalities in at-risk relatives of patient with IPF and FPF.
Study design:
Multicenter, cross-sectional study without drug and without device conducted in two major Italian tertiary referral hospitals.
The entire project is expected to last 24 months.
Study Overview
Status
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Luca Richeldi
- Phone Number: 0630157857
- Email: luca.richeldi@policlinicogemelli.it
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
The study involves two populations of study subjects:
- patients with FPF and sporadic IPF
- first-degree relatives of patients with FPF and sporadic IPF (biological relatives, not spouses).
Description
Criteria for PATIENTS:
Inclusion Criteria:
- patients aged ≥18 years when signing the informed consent
- diagnosis of IPF based on 2022 ATS/ERS/JRS/ALAT Guidelines as confirmed by the investigator based on chest HRCT scan and if available surgical lung biopsy
- diagnosis of FPF defined as the presence of fibrotic ILD in at least two members of the same biological family
- at least one 1st degree relative >40 years of age.
Exclusion Criteria:
- patients with Interstitial Lung Diseases other than Idiopathic Pulmonary Fibrosis, including but not limited to patients with granulomatous lung disease, autoimmune/collagen vascular disease associated interstitial lung disease, and drug induced interstitial lung disease
- unwilling or unable to sign informed consent
Criteria for FIRST DEGREE BIOLOGICAL RELATIVES:
Inclusion Criteria:
a. subjects aged ≥40 years
Exclusion Criteria:
- previous diagnosis of IPF
- a history of severe or poorly controlled anxiety, severe or poorly controlled depression according to the opinion of the investigators, suicidal ideation, or other psychiatric illness requiring hospitalization
- unwilling or unable to sign informed consent 400 first-degree relatives of participating patients will be recruited
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Patients with FPF and sporadic IPF
|
A chest high-resolution computed tomography (HRCT) scan will be performed
Spirometry and diffusing capacity of the lung for carbon monoxide (DLCO) measurements will be performed
Lung sounds will be recorded using a manual approach with a digital stethoscope
Clinical laboratory tests will be collected from each participant
A sample of genomic DNA from peripheral blood lymphocytes will be collected for DNA sequencing
|
|
First-degree relatives of patients with FPF and sporadic IPF
|
A chest high-resolution computed tomography (HRCT) scan will be performed
Spirometry and diffusing capacity of the lung for carbon monoxide (DLCO) measurements will be performed
Lung sounds will be recorded using a manual approach with a digital stethoscope
Clinical laboratory tests will be collected from each participant
A sample of genomic DNA from peripheral blood lymphocytes will be collected for DNA sequencing
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Prevalence of ILA
Time Frame: At subject enrollment
|
The prevalence of ILA in first-degree relatives of patients with IPF, expressed as proportion of subjects with ILAs in the overall relatives population
|
At subject enrollment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Association between ILA and genetic variants
Time Frame: At subject enrollment
|
To assess the risk of ILA in first-degree relatives of patients with FPF and sporadic IPF associated with clinically relevant mutations. Univariate and multivariate logistic regression analysis will be utilized to assess the association between genetic variants and ILA |
At subject enrollment
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 6869 (CTEP)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.